Fig. 3

Results from immunization of BALB/c mice and rhesus monkeys with pCMV-S2.S for various time periods. (A) BALB/c mice were immunized at 0, 4, and 8 weeks with 100 µg pCMV-S2.S by IM (white bars) or ID injection (gray bars) or with 1.6 µg by GG delivery (black bars). Each bar represents the group mean (±SEM) of anti-HB titer (mIU/ml) in plasma collected 4 weeks after priming or 2 weeks after each boost. End-point dilution titers were determined as the highest sample dilution resulting in an absorbance value two times that of nonimmune plasma, with a cut-off value of 0.05. Values in mIU/ml were determined from mouse standards identified by comparison with human-derived standards and the Monolisa Anti-HBs Detection Kit (Sanofi Diagnostics Pasteur). ND, not determined. (B) Rhesus monkeys were immunized at 0, 4, and 8 weeks with 1 mg pCMV-S2.S by IM (white bars) or ID injection (gray bars) or with 0.4 µg by GG delivery (black bars). Each bar represents the group mean (±SEM) of anti-HB titer (mIU/ml) in plasma collected 4 weeks after priming or 2 weeks after each boost. Values in mIU/ml were determined with human-derived standards and the Monolisa Anti-HBs Detection Kit (Sanofi Diagnostics Pasteur). (C) Rhesus monkeys were immunized at 0, 12, and 24 weeks with 1 mg pCMV-S by IM (white bars) or ID injection (gray bars) or with 3.2 µg by GG delivery (black bars). Each bar represents the group mean (±SEM) of anti-HB titer (mIU/ml) in plasma collected 4 weeks after priming or 2 weeks after each boost. Values in mIU/ml were determined with human-derived standards and the Monolisa Anti-HBs Detection Kit (Sanofi Diagnostics Pasteur).